How do CARs work?: Early insights from recent clinical studies targeting CD19. - Wikidata - awgldk - TriplyDB

How do CARs work?: Early insights from recent clinical studies targeting CD19.

How do CARs work?: Early insights from recent clinical studies targeting CD19.

http://www.wikidata.org/entity/Q36476104

about

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)Genetically modified T cells for the treatment of malignant disease Using gene therapy to manipulate the immune system in the fight against B-cell leukemias A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia CAR therapy: the CD19 paradigm Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Image-guided intrathymic injection of multipotent stem cells supports lifelong T-cell immunity and facilitates targeted immunotherapy Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.Adapting in vitro embryonic stem cell differentiation to the study of locus control regions.Biology and clinical application of CAR T cells for B cell malignancies Immunotherapy: opportunities, risks and future perspectives The basic principles of chimeric antigen receptor design.Cancer CARtography: charting out a new approach to cancer immunotherapy.CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.The value of EGFRvIII as the target for glioma vaccines.Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.Lessons learned from a highly-active CD22-specific chimeric antigen receptor.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Complete TCR-α gene locus control region activity in T cells derived in vitro from embryonic stem cells Immunooncology: Can the Right Chimeric Antigen Receptors T-Cell Design Be Made to Cure All Types of Cancers and Will It Be Covered?Driving CAR-based T-cell therapy to success.Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.Adoptive immunotherapy for cancer or viruses.Sarcoma immunotherapy: past approaches and future directions.The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors New cell sources for T cell engineering and adoptive immunotherapy.T-cell therapies for HIV: Preclinical successes and current clinical strategies.The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies.Cell-Intrinsic Barriers of T Cell-Based Immunotherapy.CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity Rejuvenated T cells attack old tumors Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

P2860

Q26773309-C014D633-C1BB-4D88-A563-BBA3987D5036 Q26783433-72D4648E-105E-4220-977E-2F974012A2CA Q26860657-24780136-542B-48C0-B13C-4AD40DF54E84 Q27011297-4C33CE71-909F-4AFB-B629-959C98C1F4BD Q27345360-FA0D478B-4D90-43CF-9C6B-0EFEC8340E02 Q28081600-0968D401-0E3E-422F-815C-E463DB8CE2E1 Q28081642-D9D57C60-2CC6-46E9-9F38-144044AB5C23 Q28085769-9C1D01DE-0829-45D4-932D-585624FCBBFC Q29617590-CD35BBF1-A2AA-4380-B0C4-3D15E1E187FB Q29620607-2974D7CD-0D0B-417C-8204-87406EBF20F5 Q33556917-C5889FAB-8985-4254-BBC9-A4F9668C0FFC Q33587034-BCD68FC1-1922-436D-992C-741843E7A9B2 Q33680320-7FEEA1D6-85D0-4C4C-8A0A-EC2C2D922E0C Q33907565-FE2C5F87-8F8D-46A7-9848-559B382ED376 Q33941012-65E22655-01FE-46CA-A8E0-0C63B4512342 Q34036213-3E2DDBBD-30FD-48FC-8F6C-0885C71A5FCE Q34139468-B7BCD549-5118-44DF-8BC9-EEF37D7DCF57 Q34667972-C544F2E2-D0E9-4677-BBC8-DEC7ECFBB418 Q35627573-ED8F1D66-467C-41CD-9A84-4C3ED0EAE098 Q36386891-77B0BCC9-852A-44B9-A164-B18729AA1B04 Q36845805-4565B696-7234-4DC4-A0C5-A52EC959E5DC Q36887833-527D35F8-4DC8-4B22-92C3-397FBF3743BE Q37127489-CC5AC59D-E4A1-401D-AEB6-7E2F407EFE54 Q37625303-E3439E1D-B3C1-4221-AF1D-FCD77F06C269 Q37715684-B8AB26D4-8DB9-41FD-826D-9AD5BAD0CB91 Q38172451-710BA239-BA34-443A-B1E7-162C8F38F188 Q38178359-B08EBB5D-BA37-4A55-BDA1-B455D56341F1 Q38207986-D7D864F5-1690-4B7B-9209-C44B1941861F Q38216836-3EFB5F5E-EE5D-42BD-98E3-8A6BC09FDC66 Q38291751-531A1AEC-C7A5-4830-98AD-C67989264ACD Q38406089-5ED06D99-3CA9-47E2-B04D-1A38E99C10C8 Q38856090-A52D8419-67F6-4C83-B49B-DA416ED629CC Q38937542-AB7308B6-1D5E-4264-98DF-441EF75A43BE Q39003162-3D002873-58B3-40A0-B548-696D3C22265E Q39122928-4E05B05A-3C58-411B-B4DA-9FCCA064B7D5 Q40965523-11136D69-9EE1-4270-A8C7-7AD30987A9CD Q41270773-AA4C435F-E769-41C1-9540-2B0F90C1B607 Q41905176-D52DF81E-F016-491C-8F3C-914307789A91 Q42097613-A226D48F-BD18-42A8-9372-6B55870A8BBD Q42702234-CFBF1FEC-A0AF-4167-AA3B-A440D4B2AF4C

P2860

How do CARs work?: Early insights from recent clinical studies targeting CD19.

http://www.wikidata.org/entity/Q36476104

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

How do CARs work?: Early insights from recent clinical studies targeting CD19.

@ast

How do CARs work?: Early insights from recent clinical studies targeting CD19.

@en

type

label

How do CARs work?: Early insights from recent clinical studies targeting CD19.

@ast

How do CARs work?: Early insights from recent clinical studies targeting CD19.

@en

prefLabel

How do CARs work?: Early insights from recent clinical studies targeting CD19.

@ast

How do CARs work?: Early insights from recent clinical studies targeting CD19.

@en

P1433

Q36476104-2FC25CF6-909A-430E-A6A4-04E07B48BF6E

P1476

Q36476104-C832C7F7-030A-4872-BD20-9526C6B8927E

P2093

Q36476104-07BF3C7F-C287-4A67-A337-158BB59C5B27

Q36476104-4A1D7D23-274C-4AC0-A230-2D044B239CCA

Q36476104-5AC8ECC2-4377-4729-B648-A560B7EF0819

Q36476104-5CDD0097-7760-4693-8467-3D78A97027D2

Q36476104-F75B9B0B-A7DC-4787-AA24-6920D7408277

P2860

Q36476104-055D1C1A-2C4F-4CB2-8CA2-2C065B108846

Q36476104-0F4F4634-EE23-44AE-B443-21DACFC4C227

Q36476104-1256AA0C-EF59-4F2D-8BE5-033BFF7696E1

Q36476104-1A77A3D3-50E2-48AC-ACBF-29286AA2CC1A

Q36476104-1C79645C-60F8-4725-AE86-58009B584AC9

Q36476104-228807C7-CEDE-4448-8B30-03F97615CBDB

Q36476104-3ABD1998-4D0D-4899-8BAD-D038866BBD7E

Q36476104-42103A8D-0ABF-4A0E-A04F-0D993376AE7B

Q36476104-484A1F9E-917E-4437-B7C0-529BABFD9D65

Q36476104-65D9CD6C-C403-4A92-A75E-603D5CF5C323

P304

Q36476104-6F014915-0185-495A-98A6-4E665F933B7F

P31

Q36476104-F5F39DF0-D492-4407-B128-E51A670058D6

P356

Q36476104-CE714A83-EE95-46FE-BEDE-9F7927C9FFCE

P433

Q36476104-079E7CCA-2CC6-4C44-B0A7-9E665D26B283

P478

Q36476104-AFCADC01-5FD3-4E0C-A00B-9A41D144E751

P577

Q36476104-F9FA19CF-2DA2-4B11-B00C-BD5C82F9810F

P5875

Q36476104-663560E0-A181-4BE7-AEB2-1261C3E1A1B3

P698

Q36476104-1BDBF4E5-DF93-4107-93AE-D5089EE4B9A6

P932

Q36476104-32E70725-EDA7-4CD7-9468-D1A3541F2D47

P356

P1433

P1476

How do CARs work?: Early insights from recent clinical studies targeting CD19.

@en

P2093

Isabelle Rivière

http://www.w3.org/2001/XMLSchema#string

Marco L Davila

http://www.w3.org/2001/XMLSchema#string

Michel Sadelain

http://www.w3.org/2001/XMLSchema#string

Renier Brentjens

http://www.w3.org/2001/XMLSchema#string

Xiuyan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

P304

1577-1583

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/ONCI.22524

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233977935

http://www.w3.org/2001/XMLSchema#string

P698

23264903

http://www.w3.org/2001/XMLSchema#string

P932

3525612

http://www.w3.org/2001/XMLSchema#string